Ultromics Can Find Hard-to-Detect Heart Failure with the Power of AI

“When a patient comes in for a routine outpatient echo, we’ll be able to help with diagnosis and reduce the misdiagnosis at that point, number one,” Ultromics’ Founder and CEO Ross Upton explains to Bloomberg Intelligence analyst Matt Henriksson about the initial benefits of EchoGo for heart failure and cardiac amyloidosis. In this episode of the Vanguards of Health Care podcast, Upton also delves into the future of diagnosing and treating heart failure with artificial intelligence, saying it can additionally “really accurately phenotype them, and so the clinician would understand after the echo is done what treatments or what next diagnostic tests the patient needs, and they would understand it there and then without having to go through and try and figure out the pieces of the puzzle.” Also tune in to learn how Ultromics plans to use to recently announced Series C financing as it commercializes EchoGo for heart failure and cardiac amyloidosis.

See omnystudio.com/listener for privacy information.